ArticleInterdisciplinary sciences, computational life sciences2022
Anti-cancer Peptide Recognition Based on Grouped Sequence and Spatial Dimension Integrated Networks.
Article in Interdisciplinary sciences, computational life sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 12 citations in OpenAlex.
- Multi-ACPNet: A multi-scale sequence-structure feature fusion framework for anticancer peptide identification and functional prediction.PLoS computational biology · 2026Article
- AACFlow: an end-to-end model based on attention augmented convolutional neural network and flow-attention mechanism for identification of anticancer peptides.Bioinformatics (Oxford, England) · 2024Article
- ACPPfel: Explainable deep ensemble learning for anticancer peptides prediction based on feature optimization.Frontiers in genetics · 2024Article
- ACP-BC: A Model for Accurate Identification of Anticancer Peptides Based on Fusion Features of Bidirectional Long Short-Term Memory and Chemically Derived Information.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
The diversification of the characteristic sequences of anti-cancer peptides has imposed difficulties on research. To effectively predict new anti-cancer peptides, this paper proposes a more suitable feature grouping sequence and spatial dimension-integrated network algorithm for anti-cancer peptide sequence prediction called GRCI-Net. The main process is as follows: First, we implemented the fusion reduction of binary structure features and K-mer sparse matrix features through principal component analysis and generated a set of new features; second, we constructed a new bidirectional long- and short-term memory network. We used traditional convolution and dilated convolution to acquire features in the spatial dimension using the memory network's grouping sequence model, which is designed to better handle the diversification of anti-cancer peptide feature sequences and to fully learn the contextual information between features. Finally, we achieved the fusion of grouping sequence features and spatial dimensional integration features through two sets of dense network layers, achieved the prediction of anti-cancer peptides through the sigmoid function, and verified the approach with two public datasets, ACP740 (accuracy reached 0.8230) and ACP240 (accuracy reached 0.8750). The following is a link to the model code and datasets mentioned in this article: https://github.com/ YouHongfeng101/ACP-DL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.